LINDSAY A MD ROSENWALD
CIK 941841 · PRESIDENT, CEO & CHAIRMAN · last filed 2026-06-26
LINDSAY A MD ROSENWALD is a PRESIDENT, CEO & CHAIRMAN who has filed 102 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing, for DERM, was dated Jun 26, 2026. Across all open-market trades the lifetime net is +$12.0M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $89.0M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$89.03M
9
102
$12.02M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DERM | Director | 397,616 | $6.31 | $2.51M | $321.4K | 8 | 2026-06-26 |
| FBIOP | PRESIDENT, CEO & CHAIRMAN | 4,586,841 | $18.76 | $86.05M | $7.68M | 24 | 2026-03-20 |
| Checkpoint Therapeutics, Inc. (CKPT) Delisted | Director | 157,007 | $4.26 | $668.8K | $356.2K | 12 | 2025-05-30 |
| AVENUE THERAPEUTICS, INC. (ATXI) Delisted | Director | 4,724 | $0.35 | $1.7K | $543.7K | 7 | 2024-09-25 |
| MBIO | Director | 1,210 | $0.63 | $764 | $758.1K | 12 | 2023-07-07 |
| FBIO | PRESIDENT, CEO | 8,000 | $3.39 | $27.1K | $1.01M | 6 | 2017-11-08 |
| Origo Acquisition Corp (CNLM.W) Delisted | Co-Chairman and CEO | 265,000 | — | — | $0 | 2 | 2016-05-23 |
| Fortress Biotech, Inc. (CNDO) Delisted | President and CEO | 4,962,304 | — | — | $1.36M | 16 | 2014-12-03 |
| NVD | 10%+ Owner | 85,506 | $5.22 | $446.3K | $0 | 1 | 2007-01-23 |
Recent Filings
102 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-26 | DERM | Grant (A) | +10,000 | $0 | EDGAR |
| 2026-03-20 | FBIOP | Grant (A) | +475,424 | $0 | EDGAR |
| 2025-08-07 | DERM | Grant (A) | +50,000 | $0 | EDGAR |
| 2025-07-07 | DERM | Grant (A) | +7,173 | $0 | EDGAR |
| 2025-05-30 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Mixed | −144,812 | $64.5K | EDGAR |
| 2025-01-03 | FBIOP | Grant (A) | +454,153 | $0 | EDGAR |
| 2024-12-17 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Grant (A) | +12,638 | $0 | EDGAR |
| 2024-09-25 | FBIOP | Buy (P) | +763,359 | $1.40M | EDGAR |
| 2024-09-25 | AVENUE THERAPEUTICS, INC. (ATXI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-07-15 | FBIOP | Buy (P) | +5,000 | $37.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.